30
CARDIOVASCULAR
hamburger
Diagnosing INOCA in Patients

How to Diagnose INOCA

The European Association of Percutaneous Cardiovascular Interventions (EAPCI) Expert Consensus Document defines ischemia and no obstructive coronary artery disease (INOCA) and guidance to its diagnosis and management. The document states that, INOCA patients present with a wide spectrum of symptoms and signs that are often misdiagnosed as non-cardiac, leading to under-diagnosis/investigation and under-treatment.1

Ischemia with Non-Obstructive Coronary Arteries (INOCA)

Guidelines Recommend Guidewire-Based Measurements

Both European and American guidelines provde a class IIa recommendation for a physiology wire-based assessment for patients with stable chest pain and/or Ischemia and No Obstructive Coronary Artery Disease (INOCA).2,3

The ESC guidelines2 2019 were updated accordingly to include an increased focus on microvascular dysfunction.

Guidewire Based Measurement Guidelines

The AHA/ACC Clinical Practice Guideline3 on chest pain includes Class IIa recommendation for guidewire-based assessment for ischemia and no obstructed coronary artery disease (INOCA) patients.

Guidewire Based Measurement Guidelines for INOCA Patients

CFR = coronary flow reserve; CMR = cardiac magnetic resonance; ECG = electrocardiogram;
FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; LAD = left anterior descending; PET = position emission tomography.

a Class of recommendation

b Level of evidence

Level-NR: Level (Quality) of Evidence Level B-NR (non-randomized): moderate-quality evidence from 1 or more well-designed, well-executed non-randomized studies, observational studies or registry studies. RCTs. Meta-analyses of such studies.
 

INOCA is Not Benign: Coronary Microvascular Dysfunction — Why Diagnosis In the Cath Lab Does Matter

Cath Lab Diagnosis of Coronary Microvascular Dysfunction (CMD)

EAPCI Consensus Document on INOCA

Aladie Chieffo MD, Milan, Italy

An updated standardization of Coronary Microvascular Dysfunction (CMD) criteria is provided by the COVADIS group including the cut-off values of CFR < 2.0 and IMR ≥ 25 that characterize CMD.1

Criteria Evidence Diagnostic Parameters
1

Symptoms of myocardial ischaemiaa

  • Effort or rest angina
  • Exertional dyspnoea
2

Absence of obstructive CAD (<50% diameter reduction or FFR >0.80)

  • Coronary CTA
  • Invasive coronary angiography
3

Objective evidence of myocardial ischaemiab

  • Presence of reversible defect, abnormality or flow reserve on a functional imaging test
4

Evidence of impaired coronary microvascular function

  • Impaired coronary flow reserve (cut-off <2.0), invasive or noninvasively determined
  • Coronary microvascular spasm, defined as reproduction of symptoms, ischaemic ECG shifts but no epicardial spasm during acetylcholine testing
  • Abnormal coronary microvascular resistance indices (e.g. IMR ≥25)

Kunadian et al. European Heart Journal. 2020; 0:1-21.

Definitive microvascular angina is only diagnosed if criterias 1, 2, 3 and 4 are present.

CAD = coronary artery disease; CCTA = coronary computed tomographic angiography; CFR = coronary flow reserve; ECG = electrocardiogram; FFR = fractional flow reserve; IMR = index of microcirculatory resistance.

a Many patients with heart failure with preserved ejection fraction would fulfil these criteria: dyspnoea, no obstructive CAD and impaired CFR. For this reason, consider measuring LV end-diastolic pressure (normal ≤10 mmHg) and NT-proBNP normal <125 pg/mL.

b Signs of ischaemia may be present but are not necessary. However, evidence of impaired coronary microvascular function should be present.
 

How to Diagnose CMD With a Comprehensive Physiology Assessment

The PressureWire™ X Guidewire and CoroFlow Cardiovascular System is a comprehensive solution for assessing both epicardial arteries and the microvasculature.4

How to Measure IMR

How to Measure IMR

Allen Jeremias, MD, New York, USA

CMD Diagnosis With Comprehensive Physiology Indices

Diagnosis With Compreshensive Physiology Indices

Colin Berry MD, PhD, Glasgow, UK

The PressureWire™ X Guidewire has pressure and temperature sensors that communicate with the CoroFlow Cardiovascular System to provide a comprehensive physiology assessment4

Pressure Wire X Guidewire and Microvascular Dysfunction Diagnosis

How to Treat Patients With CMD: Results of the CorMicA Trial

Microvascular angina and vasospastic angina are the two most common causes of INOCA, and both types of angina can be identified with diagnostic testing. The randomized CorMicA trial provides a diagnostic and treatment approach.5

The trial protocol assessed patients to determine:

CorMicA Trial Results

CorMicA Findings

Colin Berry MD, PhD, Glasgow, UK

The CorMicA results indicate a role for a more thorough investigation of coronary microvascular dysfunction among patients with INOCA, as well as an opportunity to better tailor patient treatment.5

CorMicA Trial 1-year RCT Outcomes5

CorMicA Trial 1-year RCT Outcomes

INOCA PATIENT MANAGEMENT

The EAPCI Expert Consensus Document1 defines INOCA and provides guidance to the clinical community on the diagnostic approach and management of INOCA based on existing evidence and best current practices.

INOCA Patient Management

Angiotensin-converting enzyme inhibitor = ACEI
Angiotensin receptor blocker = ARB

References

  1. Kunadian, V., et al. EAPCI Expert Consensus. Eur Heart J 2020;0:1-21.
  2. Knuuti, J., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2020:41,407-477.
  3. Gulati, M., et al. 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021;144e368-e454.
  4. PressureWire X Guidewire Instructions for Use (IFU). Refer to IFUs for additional information. CoroFlow Cardiovascular System IFU.
  5. Ford, TJ., et al. 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). J Am Coll Cardiol Intv. 2020;13:33-45.
Request Abbott Sales Rep

MAT-2112674 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.